Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| growth hormone release-stimulating peptides | 4170 | 218949-48-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Growth Hormone-Releasing Factor (GRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are primarily mediated by IGF-1 produced in the liver and in peripheral tissues. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 10, 2010 | FDA | THERATECHNOLOGIES |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 202.38 | 62.02 | 69 | 346 | 154296 | 42466624 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product dose omission issue | 98.58 | 43.56 | 32 | 173 | 321750 | 110267344 |
None
| Source | Code | Description |
|---|---|---|
| ATC | H01AC06 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists |
| FDA PE | N0000009327 | Increased GHRH Activity |
| MeSH PA | D006133 | Growth Substances |
| FDA EPC | N0000182144 | Growth Hormone Releasing Factor Analog |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy | indication | 705149003 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hypopituitarism | contraindication | 74728003 | DOID:9406 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Injury of head | contraindication | 82271004 | |
| Transsphenoidal hypophysectomy | contraindication | 171948002 | |
| Edema | contraindication | 267038008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Primary malignant neoplasm | contraindication | 372087000 | |
| Respiratory insufficiency | contraindication | 409623005 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Radiation Therapy of Cranium | contraindication | ||
| Postsurgical Complications | contraindication |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Growth hormone-releasing hormone receptor | GPCR | AGONIST | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 4030295 | VUID |
| N0000182253 | NUI |
| D06655 | KEGG_DRUG |
| 4030295 | VANDF |
| C1876200 | UMLSCUI |
| CHEBI:63626 | CHEBI |
| CHEMBL1237026 | ChEMBL_ID |
| CHEMBL2111290 | ChEMBL_ID |
| DB08869 | DRUGBANK_ID |
| C479538 | MESH_SUPPLEMENTAL_RECORD_UI |
| 6959 | IUPHAR_LIGAND_ID |
| 8786 | INN_ID |
| 901758-09-6 | SECONDARY_CAS_RN |
| MQG94M5EEO | UNII |
| 16137828 | PUBCHEM_CID |
| 1044583 | RXNORM |
| 178253 | MMSL |
| 27618 | MMSL |
| 31357 | MMSL |
| d07715 | MMSL |
| 013567 | NDDF |
| 013568 | NDDF |
| 448805009 | SNOMEDCT_US |
| 765123002 | SNOMEDCT_US |
| 785904004 | SNOMEDCT_US |
None